Comparative Pharmacology
Head-to-head clinical analysis: CUPRIC SULFATE versus MANGANESE CHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIC SULFATE versus MANGANESE CHLORIDE IN PLASTIC CONTAINER.
CUPRIC SULFATE vs MANGANESE CHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Copper is an essential trace element that serves as a cofactor for various enzymes involved in iron metabolism, connective tissue formation, and antioxidant defense. Cupric sulfate replaces copper in deficient states, enabling proper erythropoiesis, neurological function, and collagen synthesis.
Manganese chloride dissociates to provide manganese (Mn²⁺), a cofactor for enzymatic reactions including superoxide dismutase (mitochondrial), pyruvate carboxylase, and arginase. It participates in carbohydrate and lipid metabolism, bone development, and antioxidant defense.
For copper supplementation in total parenteral nutrition: 0.3-0.5 mg intravenously daily. For topical antifungal/antibacterial use: apply 2% solution or 0.1% ointment to affected area twice daily. For emetic use: 0.5-2 mg orally as a single dose.
Intravenous, 0.1 to 0.4 mg/mL as additive to parenteral nutrition, typically 1 to 5 mg per day depending on clinical status and serum levels. Frequent monitoring of manganese levels recommended.
None Documented
None Documented
Terminal elimination half-life of copper is 12-24 hours for the rapid phase, but a slower phase of 3-5 days reflects redistribution from tissues; clinical context: used for copper deficiency or as an emetic.
Terminal elimination half-life: 12-40 days (varies with body stores and nutritional status; prolonged in hepatic impairment due to reduced biliary clearance).
Primarily fecal (biliary excretion of copper) ~80%; renal excretion accounts for ~2-5% of a dose under normal conditions; small amounts lost in sweat and desquamated skin.
Renal (biliary/fecal minimal): ~90% of absorbed manganese excreted in bile into feces, with <5% renal excretion; in parenteral administration, renal elimination is negligible as manganese is predominantly cleared via hepatobiliary system.
Category C
Category C
Mineral Supplement
Mineral Supplement